Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD−3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs TD 3504 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Theravance Biopharma
- 01 Dec 2017 Status changed from recruiting to completed.
- 19 Jul 2017 Planned End Date changed from 19 Jul 2017 to 31 Aug 2017.
- 19 Jul 2017 Planned primary completion date changed from 19 Jul 2017 to 31 Aug 2017.